

Food & Function

Linking the chemistry and physics of food with health and nutrition

Accepted Manuscript

This article can be cited before page numbers have been issued, to do this please use: L. Xu, C. Yin, Y. Fan, J. Yang, D. Ming, Y. Li, W. Sun, X. Li and Y. Pi, *Food Funct.*, 2026, DOI: 10.1039/D6FO00521G.



This is an Accepted Manuscript, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this Accepted Manuscript with the edited and formatted Advance Article as soon as it is available.

You can find more information about Accepted Manuscripts in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this Accepted Manuscript or any consequences arising from the use of any information it contains.

1 **Taurine mitigates bisphenol A-induced maternal-fetal oxidative stress and**
2 **improves fetal weight by regulating Nrf2-Keap1 pathway, gut microbiota and**
3 **bile acid metabolism**

4 Lei Xu^{a, 1}, Chenggang Yin^{a, 1}, Yuyang Fan^a, Jiaqi Yang^a, Dongxu Ming^a, Yanpin Li^a,
5 Wenjuan Sun^a, Xilong Li^a, Yu Pi^{a,*}

6

7 ^aKey Laboratory of Feed Biotechnology of the Ministry of Agriculture and Rural
8 Affairs, Institute of Feed Research, Chinese Academy of Agricultural Sciences,
9 Beijing 100081, China

10 ¹These authors contributed equally to this work.

11 *Correspondence: piyu@caas.cn (Y.P.); Tel: +86-010-82108134 (Yu Pi)

12

13



15 **ABSTRACT**

16 Bisphenol A (BPA) exposure disrupts the maternal-fetal environment, resulting in
17 fetal growth restriction and tissue damage. While taurine is recognized for its
18 protective effects and its role in regulating tauro-conjugated bile acid (TCBA)
19 metabolism, its specific mechanism of action underlying BPA exposure remains
20 unclear. This study systematically investigated whether taurine alleviates
21 BPA-induced placental dysfunction, oxidative stress, and fetal weight restriction at
22 gestation day (GD) 18.5 by regulating TCBA metabolism using a murine pregnancy
23 model. Our results showed that gestational BPA exposure significantly inhibits the
24 Nrf2-Keap1 signaling pathway, triggering a vicious cycle of oxidative stress and
25 inflammation. This cascade disrupted placental nutrient transport, impaired hepatic
26 detoxification, and perturbed the gut microbiota-bile acid (BA) axis, ultimately
27 leading to fetal weight restriction at GD18.5. Taurine supplementation exerted
28 multi-level protective effects by activating the Nrf2-Keap1 pathway, upregulating the
29 expression of antioxidant genes (*CAT*, *SOD1*, *SOD2*), inhibiting pro-inflammatory
30 factors (*IL-6*, *IL-8*), and simultaneously mitigated oxidative stress and inflammatory
31 damage in the placenta and liver; restoring the expression of nutrient transport genes
32 such as syncytin B (*SynB*) and insulin-like growth factor 2 (*IGF2*) to repair placental
33 function and ensure fetal nutrient supply, while upregulating cytochrome P450 family
34 27 subfamily A member 1 (*CYP27A1*) expression to maintain hepatic BA synthesis
35 homeostasis; and remodeling the gut microbial community structure by restoring the
36 abundance of beneficial bacteria (*Muribaculaceae*, *Ruminococcus*), inhibiting the
37 abnormal proliferation of *Bifidobacterium*, and improving BA metabolic imbalance,
38 thereby normalizing the “liver-gut microbiota-BA” metabolic axis. Our findings
39 indicate that taurine mitigates BPA-induced maternal-fetal toxicity by targeting the
40 microbiota-BA-oxidative stress axis. This study highlights taurine as a promising
41 nutritional intervention strategy for protecting pregnancy against environmental
42 toxicant exposure.

43 **Keywords:** Taurine; Bisphenol A; Fetal growth restriction; Gut microbiota; Oxidative
44 stress; Bile acid metabolism



45 **Introduction**

46 Bisphenol A (BPA) is a ubiquitous environmental endocrine disruptor widely used in
47 food packaging, plastic products, and various industrial materials. Sufficient evidence
48 has demonstrated that BPA is extensively present in the environment, and humans are
49 exposed to BPA via multiple routes, including diet, skin contact, and inhalation ¹. A
50 growing body of data indicates that BPA can be detected in various human tissues ².
51 In addition, BPA has also been identified in maternal serum, breast milk, umbilical
52 cord blood, placental tissues ³, and even fetal livers ⁴. These findings clearly suggest
53 that pregnancy represents a critically sensitive window for BPA exposure.

54 Epidemiological studies have consistently shown that exposure to environmental
55 chemicals, including BPA, can induce a series of adverse pregnancy outcomes in both
56 mothers and developing fetuses, such as miscarriage ⁵, low birth weight ⁶, placental
57 abnormalities ⁷, and an increased risk of pregnancy-related complications ⁸.
58 Accumulating evidence confirms that maternal BPA exposure during pregnancy can
59 cross the placental barrier and interfere with fetal development ⁹. Animal
60 experimental studies have further validated the adverse effects of BPA: early
61 pregnancy exposure to BPA in mice can induce fetal intrauterine growth restriction
62 (IUGR) and reduce birth weight ¹⁰; BPA exposure during the embryonic and infant
63 stages in mice causes oxidative damage to the brain, liver, and kidneys ¹¹. Recent
64 studies have also emphasized that BPA exposure can induce gut microbial dysbiosis
65 in mice, thereby increasing disease susceptibility ¹². As a multifaceted regulator, gut
66 microbiota participates in various host physiological processes, including metabolism,
67 immune response, and barrier function; its dysbiosis is closely associated with
68 pathological conditions. Specifically, a study on pregnant ewes demonstrated that
69 maternal BPA exposure alters the composition of gut microbiota, which in turn
70 promotes placental apoptosis and oxidative stress, reduces placental efficiency, and
71 ultimately leads to fetal growth restriction ¹³.

72 Taurine (2-aminoethanesulfonic acid) is a conditionally essential amino acid and
73 one of the most abundant amino acids in humans and rodents, widely distributed in



74 various tissues ¹⁴. A large body of evidence has demonstrated that taurine exerts
75 prominent physiological functions primarily through antioxidant defense and
76 anti-inflammatory pathways, thereby preventing various diseases and repairing
77 damage induced by toxic substances ¹⁵. For instance, dietary taurine supplementation
78 has been reported to alleviate deoxynivalenol-induced hepatic oxidative stress,
79 mitochondrial dysfunction, apoptosis, and inflammatory responses in weaned piglets
80 ¹⁶. Another study confirmed that taurine can mitigate hepatic inflammatory responses,
81 apoptosis, and oxidative stress in weaned piglets challenged with lipopolysaccharide
82 ¹⁷. Importantly, taurine is crucial for fetal development. Mammals are unable to
83 synthesize taurine endogenously and thus rely entirely on exogenous sources ¹⁸.
84 Previous studies have shown that intraperitoneal injection of taurine into pregnant
85 mice can deliver this amino acid to both the fetal brain and liver simultaneously,
86 indicating that maternal taurine is capable of crossing the placental barrier to reach the
87 fetus ¹⁹. Recent research further reported that prenatal/postnatal taurine
88 supplementation improves neurodevelopment and brain function in mouse offspring ²⁰.
89 Additionally, maternal taurine supplementation has been shown to ameliorate
90 maternal metabolic disorders induced by fructose, such as insulin resistance and
91 systemic inflammatory dysregulation, and partially improve adverse developmental
92 outcomes in offspring ²¹. These findings collectively suggest that taurine has potential
93 protective effects on the maternal body and fetus during pregnancy. However, it
94 remains unclear whether maternal taurine supplementation can ameliorate
95 BPA-induced placental oxidative stress damage and promote fetal health.

96 Taurine serves as an indispensable and pivotal precursor for the synthesis of
97 tauro-conjugated bile acids (TCBAs), whose content and biological activity are
98 directly regulated by exogenous taurine supply levels. Accumulating evidence has
99 confirmed that exogenous taurine supplementation can directly facilitate TCBA
100 synthesis and accumulation ²². Specifically, duodenal taurine administration has been
101 shown to markedly increase the taurocholic acid conjugation rate in patients by 2.5%
102 to 10% ²³. In animal models, TCBAs represent the predominant form of BAs in
103 rodents, with over 95% of BAs conjugated to taurine in mice ²⁴. Dietary taurine



104 supplementation modulates BA metabolism in *ApoE*^{-/-} mice, which not only elevates
105 TCBA levels in the liver and serum significantly but also upregulates the expression
106 of hepatic genes related to TCBA synthesis; additionally, it alleviates atherosclerosis
107 by mitigating trimethylamine N-oxide-induced inflammatory responses²⁵. As the core
108 bioactive form of BAs, TCBA exerts multiple beneficial regulatory functions via
109 activating farnesoid X receptor (*FXR*) and G protein-coupled BA receptor (*TGR5*)²⁶.
110 These functions specifically include maintaining glucose metabolic homeostasis,
111 regulating the structural balance of gut microbiota²⁷, alleviating oxidative
112 stress-induced damage, and reducing inflammatory responses²⁸, thereby providing
113 critical support for systemic health.

114 Although the maternal-fetal protective effects of taurine and the regulatory
115 functions of TCBA have been independently verified, systematic investigations
116 remain scarce regarding whether taurine can exert maternal-fetal protective effects by
117 regulating TCBA metabolism under gestational BPA exposure. Specifically, it is
118 unclear if taurine can alleviate BPA-induced placental dysfunction, maternal-fetal
119 oxidative stress, and fetal low birth weight. In view of this, the present study
120 hypothesizes that maternal taurine supplementation during pregnancy can
121 synergistically activate antioxidant and anti-inflammatory pathways by promoting
122 TCBA synthesis, thereby attenuating BPA-induced placental injury and relieving
123 maternal-fetal oxidative stress. This study aims to clarify the protective effects of
124 taurine against BPA-induced maternal-fetal oxidative stress, placental dysplasia, and
125 fetal low birth weight, as well as to elucidate the underlying mechanisms. Collectively,
126 findings from this study will provide novel insights into the preventive and
127 interventional strategies for BPA-induced adverse pregnancy outcomes.

128 **Material and methods**

129 **Animal welfare statement**

130 The animal experimental protocol employed in this study was approved by the
131 Animal Care of the Feed Research Institute, Chinese Academy of Agricultural
132 Sciences (Approval No.: IFR-CAAS20240702).



133 **Experimental animals and design**

134 In the present study, 30 specific pathogen-free (SPF) grade C57BL/6J female mice
135 and 15 male mice were selected and caged overnight for mating at a female-to-male
136 ratio of 2:1. On the following day, the formation of vaginal plugs was checked;
137 female mice with visible vaginal plugs were confirmed as pregnant, housed
138 individually, and the day of vaginal plug detection was designated as gestation day
139 (GD) 0.

140 The pregnant mice were randomly divided into three groups (n = 10 per group):
141 the control group, the BPA group, and the BPA+Tau group. All pregnant mice were
142 fed a basal breeding diet, and interventions were administered via intragastric gavage:
143 the control group was gavaged with 0.2 mL of corn oil daily; the BPA group was
144 gavaged with 0.2 mL of corn oil containing 200 mg/kg BW BPA daily; and the
145 BPA+Tau group was gavaged with 0.2 mL of corn oil containing 200 mg/kg BW
146 BPA and 500 mg/kg BW taurine daily. The experimental procedure is illustrated in
147 **Fig. 1**. The doses of BPA and taurine were selected in accordance with previous
148 studies^{29, 30}. BPA ($\geq 99\%$ purity) was purchased from Sigma-Aldrich; Taurine (\geq
149 99% purity) and corn oil were purchased from Shanghai Yuanye Biotechnology Co.,
150 Ltd. The experimental period lasted for 18.5 days; during this period, the body
151 weights of the pregnant mice were recorded on the 1st day of pregnancy and the
152 18.5th day of pregnancy, respectively.

153 **Sample collection**

154 On GD 18.5, blood samples were collected from the retro-orbital venous plexus,
155 followed by euthanasia of the pregnant mice via cervical dislocation for subsequent
156 sample processing. The collected whole blood was placed in sterile anticoagulant-free
157 centrifuge tubes and allowed to stand at room temperature for 2 h to ensure complete
158 coagulation. Subsequently, the samples were centrifuged at 4000 r/min for 10 min at 4
159 °C. The upper pale yellow serum was carefully aspirated, aliquoted into sterile
160 cryopreservation tubes, and stored at -80 °C for subsequent detection and analysis of
161 maternal-fetal related oxidative stress, inflammatory factors, and metabolic indicators.
162 For tissue samples, fetal placentas of pregnant mice and livers from both dams and



163 fetuses were harvested. The litter size was recorded, and fetal, placental weights were
164 measured. IUGR was defined as fetal body weight below the mean – 2 SD of the
165 control group, and the IUGR rate was calculated accordingly³¹. The placental and
166 hepatic tissues were placed in cryovials and preserved at -80°C for subsequent gene
167 expression analysis.

168 **Determination of serum and placental antioxidant enzyme activity and** 169 **inflammatory cytokines**

170 Before detection, the placental tissues were fully ground. An appropriate amount of
171 placental tissue was homogenized in 1.0 mL of pre-chilled phosphate-buffered saline
172 (PBS, pH 7.4) using a tissue homogenizer. Subsequently, the homogenate was
173 centrifuged at 3500 rpm for 10 min at 4°C, and the supernatant was collected for
174 subsequent assays. The protein concentration of tissue supernatant was determined by
175 BCA (Bicinchoninic Acid) protein assay kit (Huaxing Bio, Beijing, China) in strict
176 accordance with the manufacturer's instructions. Bovine serum albumin (BSA) was
177 used as the standard to establish a standard curve, and the absorbance value was
178 measured at 562 nm with a microplate reader (BioTek Epoch, Agilent Technologies,
179 USA). The protein concentration of each sample was calculated according to the
180 standard curve. The activities of antioxidant enzymes, including superoxide dismutase
181 (SOD) and total antioxidant capacity (T-AOC), as well as the oxidative damage
182 marker malondialdehyde (MDA), were determined in serum and placental tissue
183 using specific commercial assay kits (Nanjing Jiancheng Bioengineering Institute,
184 Nanjing, China). The concentrations of inflammatory cytokines tumor necrosis
185 factor- α (TNF- α), interleukin-1 β (IL-1 β), and interleukin-6 (IL-6) in serum and
186 placental tissue were measured by mouse-specific enzyme-linked immunosorbent
187 assay (ELISA) kits (Enzyme-Linked Biotechnology Co., Ltd., Shanghai, China).

188 **RT-qPCR**

189 Total RNA was extracted from the placental and hepatic tissues of pregnant mice
190 using the i-presci Scientific RNA Extraction Kit. Following the determination of RNA
191 concentration and quality, reverse transcription was performed with the PrimeScript®
192 RT Reagent Kit with gDNA Eraser (Takara, Japan) to eliminate genomic DNA



193 contamination before complementary DNA (cDNA) synthesis. Quantitative real-time
194 polymerase chain reaction (RT-qPCR) was subsequently conducted on a Bio-Rad
195 CFX96 Real-Time PCR System. Relative mRNA expression levels were normalized
196 to β -actin and calculated using the $2^{-(\Delta\Delta Ct)}$ method³². The sequences of the
197 primers used in this study are provided in **Table S1**.

198 **16S rRNA gene sequencing analysis of fecal microbiome**

199 Following the procedures described in previous studies³³, Total microbial DNA was
200 extracted from frozen fecal samples using the Fast DNA Extraction Kit (Omega
201 Bio-Tek, Norcross, GA, USA) in accordance with the manufacturer's optimized
202 protocol. DNA quality was comprehensively evaluated: integrity was verified by
203 1.0% agarose gel electrophoresis, while concentration and purity were determined
204 using a NanoDrop™ 2000 spectrophotometer (Thermo Fisher Scientific, Waltham,
205 MA, USA) by measuring the absorbance ratios A260/A280 (1.8–2.0, indicating
206 minimal protein contamination) and A260/A230 (>1.5, reflecting low polysaccharide
207 or salt interference). Only DNA samples with intact electrophoretic bands (no obvious
208 degradation) and a concentration ≥ 50 ng/ μ L were selected as templates for PCR
209 amplification. The specific primer pairs 338F
210 (5'-ACTCCTACGGGAGGCAGCAG-3') and 806R
211 (5'-GGACTACHVGGGTWTCTAAT-3') were used to amplify the hypervariable
212 V3-V4 regions of the bacterial 16S rRNA gene³⁴.

213 Paired-end sequencing (2×250 bp) was performed on the Illumina MiSeq
214 platform to acquire raw sequence data. Raw reads were quality-controlled and
215 denoised using the DADA2 plugin integrated in QIIME 2 (v2022.2) with customized
216 parameters to generate high-resolution amplicon sequence variants (ASVs).
217 Taxonomic assignment of ASVs was achieved by alignment against the SILVA 138.2
218 database with a confidence threshold of 80%.

219 Subsequently, systematic bioinformatics analyses were performed using the
220 Majorbio Cloud Platform (<https://cloud.majorbio.com/>), encompassing taxonomic
221 composition analysis, microbial community diversity assessment (α -diversity and
222 β -diversity), intergroup difference testing, correlation analysis, phylogenetic tree



223 construction, and functional potential prediction. α -diversity indices, including
224 Shannon, Chao1, ACE, and Simpson, were calculated to quantify the species richness
225 and evenness of the community. β -diversity was visualized via principal coordinate
226 analysis (PCoA) based on weighted UniFrac distances, intuitively reflecting
227 intergroup differences in community structure. For intergroup microbial community
228 difference testing, the Kruskal–Wallis test was employed for multiple-group
229 comparisons; Spearman’s rank correlation analysis was used for correlation analysis.
230 Based on 16S rRNA gene sequencing data, the PICRUSt2 tool (version 2.2.0-b) was
231 employed with default parameters to predict functional potential. Amplicon sequences
232 were projected to functional profiles using the built-in IMG reference genome
233 database, followed by annotation against the Kyoto Encyclopedia of Genes and
234 Genomes (KEGG) database for classification.

235 **Serum BA profile detection**

236 The targeted BA metabolomics detection was performed with reference to the
237 methods previously reported in the literature³³. Due to serum hemolysis in the CON
238 group and BPA + Tau group, one sample from each group was excluded from
239 subsequent analyses to ensure data reliability.

240 Before detection, serum samples were subjected to preprocessing procedures,
241 including protein precipitation, liquid-liquid extraction, and centrifugation (detailed
242 parameters were consistent with the referenced method), to remove interfering
243 substances and enrich the target BA components. The pretreated samples were then
244 analyzed using ultra-performance liquid chromatography-tandem mass spectrometry
245 (UPLC-MS/MS, ACQUITY UPLC Xevo TQ-S, Waters Corp., Milford, MA, USA)
246 for the qualitative and quantitative determination of analytes.

247 Raw mass spectrometry data were collected and processed using MassLynx
248 software (v4.1, Waters Corp., Milford, MA, USA), including peak alignment, peak
249 picking, and peak area integration. Subsequent targeted metabolomics analysis of the
250 identified BAs was conducted on the Majorbio Cloud Platform
251 (<https://cloud.majorbio.com/>) for data visualization and systematic interpretation.

252 **Statistical analysis**



253 Statistical analyses of reproductive performance, antioxidant enzyme indices,
254 inflammatory cytokines in serum and placental tissues, and quantitative real-time
255 PCR results were performed using SPSS statistical software (Version 25.0). One-way
256 ANOVA was performed for multi-group comparisons, with the least significant
257 difference (LSD) test used to determine significant differences. Intergroup
258 comparisons of α -diversity (Shannon index, Simpson index) and relative abundances
259 of dominant taxa (phylum and genus levels) were conducted via the Wilcoxon
260 rank-sum test. Spearman's rank correlation analysis was applied to explore
261 associations among serum oxidative stress markers, inflammatory cytokines, gut
262 microbiota (at the genus level), and serum BAs, and correlation heatmaps were
263 generated using R software (v4.4.2). Data are presented as the mean \pm standard error
264 (SE), with a P -value < 0.05 considered statistically significant and a P -value between
265 0.05 and 0.10 regarded as a significant trend.

266 Results

267 Maternal taurine supplementation on reproductive performance in pregnant 268 mice exposed to bisphenol A (BPA)

269 The results of reproductive performance are presented in **Table 1**. Compared with the
270 control group, maternal BPA exposure did not significantly affect the incidence of
271 IUGR, but it markedly reduced the average placental weight, fetal weight and total
272 litter size ($P < 0.05$). In contrast, taurine supplementation significantly increased fetal
273 weight and total litter size relative to the BPA-exposed group ($P < 0.05$).

274 Maternal taurine supplementation on serum and placental tissues antioxidant 275 enzyme activities and inflammation-related markers in pregnant mice exposed to 276 bisphenol A (BPA)

277 The activities of antioxidant enzymes and levels of inflammation-related markers in
278 serum and placental tissues of pregnant mice are shown in **Fig. 2**. In terms of
279 antioxidant capacity (**Fig. 2-A, 2-C**), BPA exposure significantly disrupted the redox
280 balance in serum and placental tissues. Compared with the CON group, the
281 BPA-exposed group showed significantly decreased SOD activity in serum ($P < 0.01$)



282 and placental tissue ($P < 0.05$), along with significantly increased serum MDA levels
283 ($P < 0.001$), and a significant decrease in T-AOC in placental tissue ($P < 0.05$).
284 Taurine supplementation effectively reversed these BPA-induced abnormalities: it
285 significantly upregulated SOD activity in serum and placental tissue ($P < 0.05$), while
286 downregulating serum MDA levels ($P < 0.001$), and enhancing serum T-AOC ($P <$
287 0.05). These findings indicate that taurine supplementation effectively alleviates
288 BPA-induced placental oxidative stress.

289 Regarding inflammatory cytokine responses, BPA exposure triggered abnormal
290 inflammatory responses in serum and placental tissues (**Fig. 2-B, 2-D**). Compared
291 with the CON group, the BPA-exposed group showed a significant increase in the
292 levels of the pro-inflammatory cytokine IL-6 in serum ($P < 0.01$) and placental tissue
293 ($P < 0.05$), while taurine supplementation significantly reduced IL-6 levels in serum
294 ($P < 0.001$) and placental tissue ($P < 0.05$). Furthermore, compared with the BPA
295 group, the taurine-supplemented group exhibited a significant decrease in serum
296 IL-1 β ($P < 0.01$) and TNF- α levels ($P < 0.05$). These results suggest that taurine
297 supplementation exerts a prominent mitigating effect on BPA-induced placental
298 inflammation.

299 **Maternal taurine supplementation on the expression levels of placental function,**
300 **antioxidant, and inflammatory cytokine-critical genes in placental tissues of**
301 **BPA-exposed pregnant mice**

302 Placental development-related genes directly determine the structural integrity and
303 physiological function of the placenta, which is essential for maternal-fetal nutrient
304 exchange and barrier protection. To systematically evaluate the protective effects of
305 taurine against BPA-induced placental impairment, we analyzed the mRNA
306 expression of placental function-critical genes, antioxidant pathway genes, and
307 inflammatory cytokine genes (**Fig. 3**).

308 As shown in **Fig 3-A**, BPA exposure significantly impaired the expression of
309 genes essential for placental development and function. Compared with the CON
310 group, the BPA-exposed group exhibited a significant downregulation of *syncytinB*
311 and *IGF2* mRNA expression in the placenta ($P < 0.05$). Taurine supplementation



312 effectively reversed these deficits, significantly upregulating *syncytinB* and *IGF2*
313 mRNA expression ($P < 0.05$). In contrast, neither BPA exposure nor taurine
314 supplementation exerted significant effects on the mRNA expression of *PLGF* or
315 *FGF15*.

316 Concurrent with the impairment of placental development genes, BPA exposure
317 significantly disrupted the Nrf2-Keap1 antioxidant axis in placental tissues (**Fig. 3-B**).
318 Compared with the CON group, *Nrf2* mRNA expression was remarkably
319 downregulated ($P < 0.01$), while its negative regulator *Keap1* ($P < 0.01$) and
320 downstream target gene *NQO1* ($P < 0.001$) were significantly upregulated. This
321 suggests that BPA impairs placental antioxidant capacity by suppressing
322 Nrf2-mediated cytoprotective signaling. In addition, taurine supplementation
323 effectively reversed these BPA-induced abnormalities: it significantly elevated *Nrf2*
324 mRNA expression ($P < 0.01$) and inhibited *Keap1* overexpression ($P < 0.01$), while
325 exerting no significant effect on *NQO1*. Furthermore, relative to the BPA group,
326 taurine supplementation markedly enhanced the mRNA expression of core
327 antioxidant enzymes *CAT* and *SOD1* ($P < 0.01$). Collectively, these results indicate
328 that taurine alleviates BPA-induced placental oxidative stress through activating the
329 Nrf2-Keap1 pathway, thereby enhancing the transcriptional levels of downstream
330 antioxidant enzymes to restore placental redox homeostasis.

331 In addition to oxidative stress, BPA exposure triggered a robust
332 pro-inflammatory response in the placenta (**Fig. 3-C**), which may synergistically
333 damage placental function with oxidative stress. Compared with the CON group, BPA
334 exposure significantly upregulated the mRNA expression of pro-inflammatory
335 cytokines *IL-6* ($P < 0.01$), *IL-8* ($P < 0.01$), and *IL-1 β* ($P < 0.001$). Relative to the BPA
336 group, Taurine supplementation exerted a potent anti-inflammatory effect by
337 significantly attenuating the BPA-induced overexpression of *IL-6*, *IL-8*, and *IL-1 β* .
338 Additionally, taurine slightly increased anti-inflammatory *IL-10* expression ($P =$
339 0.071), which may contribute to rebalancing the placental inflammatory
340 microenvironment. Collectively, these regulatory effects of taurine mitigate
341 BPA-induced placental damage.



342 **Maternal taurine supplementation on the expression levels of antioxidant,**
343 **inflammatory cytokine, and bile acid synthesis-critical genes in liver tissues of**
344 **BPA-exposed pregnant mice**

345 As the core organ of metabolism and detoxification in the maternal body, the liver
346 plays a pivotal role in regulating systemic redox balance, inflammatory responses, and
347 bile acid synthesis. So, we analyzed the mRNA expression profiles of key genes
348 involved in antioxidant defense, inflammatory regulation, and BA synthesis in the
349 liver tissues of BPA-exposed pregnant mice (**Fig. 4**).

350 As shown in **Figure 4-A**, BPA exposure significantly disrupted the
351 Nrf2-mediated antioxidant signaling pathway in the maternal liver. Compared with
352 the CON group, BPA exposure significantly downregulated *Nrf2* mRNA expression
353 in maternal liver ($P < 0.05$), while its negative regulator *Keap1* ($P < 0.05$) and
354 downstream gene *NQO1* ($P < 0.001$) were significantly upregulated. Taurine
355 supplementation effectively reversed these BPA-induced abnormalities, significantly
356 elevated *Nrf2* mRNA expression, and inhibited *Keap1* overexpression ($P < 0.05$),
357 with a trend toward decreased *NQO1* expression ($P = 0.055$). Additionally, versus the
358 BPA group, taurine supplementation significantly elevated the mRNA expression of
359 antioxidant enzymes *CAT* ($P < 0.05$) and *SOD1* ($P < 0.01$), and also significantly
360 elevated the mRNA expression of *SOD2* ($P < 0.05$). Collectively, these results
361 indicate that taurine antagonizes BPA-induced hepatic oxidative stress by activating
362 Nrf2, suppressing Keap1, and thereby enhancing the transcriptional levels of
363 downstream antioxidant enzymes, which Consistent with the oxidative stress observed
364 in placental tissues.

365 Parallel to the placental inflammatory response, BPA exposure also triggered a
366 prominent pro-inflammatory cascade in maternal liver (**Fig. 4-B**). compared with the
367 CON group, BPA exposure significantly upregulated the mRNA expression of
368 pro-inflammatory cytokines *IL-6* and *IL-8* ($P < 0.001$). Taurine supplementation
369 exerted a potent anti-inflammatory effect by significantly suppressing the
370 BPA-induced overexpression of *IL-6* and *IL-8* ($P < 0.01$). Furthermore, no significant
371 differences in *IL-1 β* or *TNF- α* mRNA expression were observed among all



372 experimental groups. Intriguingly, taurine also significantly upregulated the
373 transcription of *PPAR γ* , a nuclear receptor known to cross-talk with inflammatory and
374 oxidative stress pathways.

375 As the core organ responsible for BA synthesis, the liver's BA metabolic
376 homeostasis is critical for maintaining maternal nutrient absorption and detoxification
377 functions. Regarding BA synthesis-critical genes (**Fig. 4-C**), BPA exposure had no
378 significant impact on the mRNA expression of core genes in the FXR signaling
379 pathway—including *FXR*, *CYP7A1*, and *CYP7B1* ($P > 0.05$), which suggested that
380 BPA does not disrupt FXR-mediated BA synthesis in maternal liver (**Fig. 4-C**).
381 However, relative to the BPA group, taurine supplementation significantly elevated
382 the mRNA expression of *CYP27A1* ($P < 0.05$), which indicates that taurine
383 specifically targets *CYP27A1* to enhance BA synthesis.

384 **Maternal taurine supplementation on the expression levels of antioxidant,** 385 **inflammatory cytokine, and bile acid synthesis-critical genes in fetal liver tissues** 386 **of BPA-exposed pregnant mice**

387 Maternal BPA exposure is known to potentially impair fetal liver development. Thus,
388 we detected the mRNA expression of key genes involved in antioxidant defense and
389 inflammatory regulation in fetal liver tissues (**Fig. 5**). As shown in **Fig. 5-A**,
390 BPA-induced maternal hepatic and placental oxidative stress were mirrored in the
391 fetal liver. Compared with the CON group, the BPA group significantly
392 downregulated the mRNA expression of *CAT* ($P < 0.05$) and *SOD2* ($P < 0.01$).
393 Taurine supplementation significantly upregulated *SOD2* mRNA expression ($P <$
394 0.05), thereby restoring fetal hepatic antioxidant capacity. Similar results regarding
395 inflammatory responses (**Fig. 5-B**), BPA exposure triggered pro-inflammatory
396 activation in the fetal liver. Compared with the CON group, the BPA group
397 significantly upregulated the mRNA expression of pro-inflammatory cytokines *IL-8*
398 and *TNF- α* ($P < 0.05$), which promoted inflammatory reactions. Taurine
399 supplementation exerted targeted anti-inflammatory effects: relative to the BPA group,
400 which significantly suppressed the overexpression of *IL-8* and *TNF- α* ($P < 0.05$), thus
401 mitigating BPA-induced fetal hepatic inflammation. Additionally, no significant



402 differences in *IL-6* or *IL-1 β* mRNA expression were observed among all groups ($P >$
403 0.05).

404 **Maternal taurine supplementation on fecal microbiota in BPA-exposed pregnant** 405 **mice**

406 To investigate the effect of taurine supplementation on the gut microbiota of pregnant
407 mice, we analyzed the composition, structure, and functional potential of the fecal
408 microbiota in pregnant mice, as well as its correlation with maternal serum oxidative
409 stress and inflammatory markers (**Fig. 6-7**). Alpha diversity analysis (**Fig. 6 A-B**)
410 demonstrated that maternal BPA exposure significantly disrupted the diversity of the
411 fecal gut microbiota. Compared with the BPA-exposed group, taurine
412 supplementation notably increased the Shannon index ($P < 0.05$) and concurrently
413 decreased the Simpson index ($P < 0.05$) of the fecal gut microbiota. Given that the
414 Shannon index reflects the species richness and evenness of the microbial community,
415 while the Simpson index characterizes community dominance, these results suggest
416 that taurine can effectively reverse BPA-induced alpha diversity dysbiosis of the gut
417 microbiota and contribute to maintaining the homeostasis of the intestinal
418 microecosystem.

419 Furthermore, PCoA based on weighted UniFrac distance (**Fig. 6-C**) revealed
420 distinct clustering patterns among the three groups. The microbial community
421 structure of the BPA-exposed group was significantly separated from that of the CON
422 group. In contrast, the community of the BPA+Tau group clustered closely with the
423 CON group and exhibited a distinct structural difference from the BPA group
424 (ANOSIM: $R = 0.2217$, $P < 0.05$). This result confirms that taurine supplementation
425 remarkably reverses the overall community structure disorder of fecal gut microbiota
426 caused by BPA treatment.

427 As shown in the Venn diagram analysis of ASVs (**Fig. S1A**), a total of 489
428 shared ASVs were identified among the three groups. Regarding the number of
429 unique ASVs, the CON group (1574) had a higher count than the BPA group (1453),
430 while the BPA+Tau group (1572) showed a count comparable to that of the CON



431 group, indicating that taurine is conducive to reversing the microbial community
432 disorder induced by BPA.

433 Analysis of community composition at the phylum level revealed that the fecal
434 microbiota of the three treatment groups was predominantly composed of five phyla,
435 namely Bacteroidota, Firmicutes, Actinobacteriota, Verrucomicrobiota, and
436 Proteobacteria (**Fig. S1-B**). Specifically, their relative abundances were as follows: in
437 the CON group, Bacteroidota accounted for 60.54%, Firmicutes for 30.61%,
438 Actinobacteriota for 1.42%, Verrucomicrobiota for 2.34%, and Proteobacteria for
439 1.74%; in the BPA group, the relative abundances were 39.08% (Bacteroidota),
440 47.95% (Firmicutes), 5.25% (Actinobacteriota), 2.84% (Verrucomicrobiota), and
441 2.83% (Proteobacteria); in the BPA+Tau group, they were 55.55% (Bacteroidota),
442 36.23% (Firmicutes), 2.11% (Actinobacteriota), 2.17% (Verrucomicrobiota), and
443 1.43% (Proteobacteria). Additionally, the Firmicutes/Bacteroidota ratio (F/B) ratio
444 was 0.5, 1.22, and 0.65 in the CON, BPA, and BPA+Tau groups, respectively. This
445 suggests BPA exposure significantly increased the F/B ratio, which was mitigated by
446 taurine supplementation.

447 Further analysis of phylum-level differences (**Fig. S1C**) showed that compared
448 with the CON group, the BPA group exhibited significant alterations in gut
449 microbiota composition: the relative abundances of Firmicutes and Actinobacteria
450 were significantly increased ($P < 0.05$), while the relative abundance of Bacteroidota
451 was significantly decreased ($P < 0.05$). These results indicate that BPA exposure
452 induces structural imbalance of gut microbiota at the phylum level. Notably, relative
453 to the BPA group, the BPA+Tau group showed significantly reduced relative
454 abundances of Actinobacteria and Firmicutes ($P < 0.05$) and a significantly increased
455 relative abundance of Bacteroidota ($P < 0.05$).

456 At the genus level, the three treatment groups were dominated by three taxa with
457 the highest relative abundances: norank_f_Muribaculaceae (Muribaculaceae family,
458 unclassified genus), *Lactobacillus*, and *Dubosiella* (**Fig. 7-A**). Specifically, the
459 relative abundance of norank_f_Muribaculaceae was 52.88% in the CON group,
460 35.80% in the BPA group, and 50.72% in the BPA+Tau group; *Lactobacillus*



461 accounted for 8.69% (CON), 12.73% (BPA), and 9.39% (BPA+Tau); *Dubosiella*
462 exhibited relative abundances of 2.86% (CON), 15.60% (BPA), and 8.96%
463 (BPA+Tau).

464 Genus-level differential analysis (**Fig. 7B-C, Fig. S1D**) revealed that compared
465 with the CON group, the BPA group significantly upregulated the relative abundances
466 of *Dubosiella*, *Bacillus*, and *Bifidobacterium* ($P < 0.05$), while significantly
467 downregulating the abundances of *norank_f_Muribaculaceae*, *Alistipes*, *Rikenella*,
468 and *Ruminococcus* ($P < 0.05$). In contrast, taurine supplementation alleviated the
469 aforementioned abnormal changes in certain genera. Compared with the BPA group,
470 the BPA+Tau group significantly increased the abundances of
471 *norank_f_Muribaculaceae* and *Ruminococcus* that were previously suppressed by
472 BPA ($P < 0.05$). Meanwhile, it significantly reduced the overexpressed abundance of
473 *Bifidobacterium* in the BPA group ($P < 0.05$).

474 In addition, a correlation analysis was performed to explore the potential
475 associations between serum oxidative stress, inflammatory markers, and fecal
476 microbiota in BPA-exposed pregnant mice supplemented with taurine (**Fig. 7-D**). The
477 results showed that SOD activity positively correlated with
478 *norank_f_Muribaculaceae* abundance ($P < 0.05$) and negatively correlated with
479 *Bifidobacterium* and *norank_o_Clostridia_UCG-014* abundances; MDA positively
480 correlated with *unclassified_f_Atopobiaceae* abundance and negatively correlated
481 with *norank_f_Muribaculaceae* and *Alistipes* abundances; TNF- α positively
482 correlated with *Lachnospiraceae_NK4A136_group* and *Helicobacter* abundances;
483 IL-1 β positively correlated with *Ileibacterium* and *Parasutterella* abundances; IL-6
484 positively correlated with *Dubosiella* and *Bifidobacterium* abundances and negatively
485 correlated with *Alistipes* abundance.

486 Functional prediction analysis based on KEGG pathway abundance (**Fig. S1 E**)
487 and enzyme abundance (**Fig. S1 F**) revealed that compared with the CON group, the
488 BPA group significantly downregulated the predicted abundance of the bile acid: Na+
489 symporter (BASS family) gene pathway ($P < 0.05$) and significantly upregulated the
490 functional abundance of 7 α -hydroxysteroid dehydrogenase (7 α -HSDH), an enzyme



491 involved in BA metabolism ($P < 0.05$). In contrast, taurine supplementation increased
492 the abundance of the bile acid: Na⁺ symporter (BASS family) gene pathway, though
493 this change did not reach statistical significance. Taurine supplementation
494 significantly downregulated the functional abundance of 7 α -HSDH, restoring it to the
495 normal level observed in the CON group ($P < 0.05$).

496 **Maternal taurine supplementation on the serum bile acid metabolism of** 497 **BPA-exposed pregnant mice**

498 Targeted ultra-performance liquid chromatography-tandem mass spectrometry
499 (UPLC-MS/MS) was employed to comprehensively profile the serum BA metabolism
500 in pregnant mice (**Fig. 8**). Principal component analysis (PCA) (**Fig. 8-A**) revealed
501 distinct separation of BA metabolic profiles among the CON group, BPA-exposed
502 group, and BPA+Tau group, indicating pronounced inter-group differences in BA
503 homeostasis. Further analysis of serum BA relative abundance showed that all three
504 groups shared a core composition dominated by five key BAs (**Fig. 8-B**): taurocholic
505 acid (TCA), 23-nordeoxycholic acid (23_NDCA), tauro- β -muricholic acid (T β MCA),
506 β -muricholic acid (β MCA), and cholic acid (CA). Differential BA analysis (**Fig.**
507 **8C-Q**) demonstrated that BPA exposure induced significant metabolic dysregulation
508 relative to the CON group: specifically, the serum concentrations of conjugated BAs
509 (including glycocholic acid (GCA), TCA, taurochenodeoxycholic acid (TCDCA),
510 tauro- α -muricholic acid (T α MCA), T β MCA, tauro- γ -muricholic acid (T γ MCA), and
511 tauro- ω -muricholic acid (T ω MCA)) as well as total TCBA were markedly
512 downregulated; in contrast, the concentration of apocholic acid (ACA) was
513 significantly elevated ($P < 0.05$), while tauoursodeoxycholic acid (TUDCA) and
514 deoxycholic acid (DCA) exhibited a non-significant downward trend ($0.05 < P <$
515 0.10). For the BPA+Tau group, significant reductions were observed in the
516 concentrations of TCDCA, TUDCA, ACA, tauroolithocholic acid (TLCA),
517 glycodeoxycholic acid (GDCA), isolithocholic acid (ILCA), DLCA, T ω MCA ($P <$
518 0.05), while TCBA, GCA, T α MCA, and T β MCA showed a non-significant
519 decreasing trend ($0.05 < P < 0.10$). These results suggest that taurine can partially
520 restore the BPA-induced reduction in these BA levels. Compared with the BPA group,



521 the BPA+Tau group effectively reversed the abnormal elevation of ACA. In addition,
522 all BA constituents created an interconnected network characterized by dense positive
523 correlations, notably with taurine-conjugated BAs aggregating into a separate cluster
524 (**Fig. 8R**). This pattern suggests a highly synergistic nature of BA metabolism, where
525 changes in individual components can trigger cascading effects on others, elucidating
526 the mechanism behind the widespread metabolic dysregulation caused by BPA.

527 Correlation analysis between differential BAs, oxidative stress markers (MDA,
528 T-AOC, SOD), and inflammatory cytokines (IL-6, IL-1 β , TNF- α) identified several
529 significant associations (**Fig. 8S**): glycochenodeoxycholic acid (GCDCA) was
530 positively correlated with SOD ($P < 0.05$) and negatively correlated with MDA ($P <$
531 0.05); glyoursodeoxycholic acid (GUDCA) was negatively correlated with MDA (P
532 < 0.05); T β MCA was positively correlated with SOD ($P < 0.05$); T γ MCA was
533 negatively correlated with IL-6 ($P < 0.05$); ILCA was positively correlated with
534 TNF- α ($P < 0.01$); and T ω MCA was negatively correlated with both IL-6 ($P < 0.01$)
535 and MDA ($P < 0.05$), while positively correlated with SOD ($P < 0.05$).

536 Discussion

537 Bisphenol A, a ubiquitous environmental endocrine disruptor, can perturb the
538 physiological homeostasis of the maternal-fetal unit during the critical developmental
539 sensitive window of pregnancy, triggering a variety of adverse pregnancy outcomes
540 and posing a significant threat to maternal reproductive health and fetal growth and
541 development. Fetal weight at GD18.5 and total litter size are key indicators for
542 evaluating maternal reproductive performance and fetal developmental potential.
543 Consistent with previous studies reporting adverse effects of maternal BPA exposure
544 during pregnancy on both dams and fetuses^{9, 10}, our findings demonstrated that
545 maternal BPA exposure during gestation significantly reduced fetal weight at GD18.5
546 and total litter size. Taurine supplementation effectively reversed these BPA-induced
547 adverse phenotypes, which highlights the critical role of taurine in antagonizing
548 BPA-induced maternal-fetal toxicity and protecting maternal-fetal health. Herein, we
549 systematically explore the potential protective mechanisms of taurine by integrating



550 the main findings of the present study.

View Article Online
DOI: 10.1039/D6FO00521G

551 Oxidative stress and aberrant inflammatory responses are well recognized as key
552 mediators of BPA-induced multi-organ toxicity, and their synergistic effects
553 constitute an important pathological mechanism triggering tissue damage and adverse
554 outcomes. Accumulating evidence has indicated that prenatal BPA exposure elicits
555 maternal inflammatory responses, exacerbates oxidative stress, and impairs
556 antioxidant capacity^{35, 36}. Disruption of redox homeostasis and the occurrence of
557 aberrant inflammatory responses in maternal and fetal tissues are closely associated
558 with the pathogenesis of adverse pregnancy outcomes. Previous studies have reported
559 that low-dose BPA can induce liver damage in pregnant mice and their offspring
560 through the synergistic effects of oxidative stress and inflammatory responses,
561 including downregulating the activity of hepatic antioxidant enzymes and
562 upregulating the expression of the proinflammatory cytokine *IL-1 β* as well as the
563 proapoptotic factors AIF and Bax³⁷. Consistent with these findings, analogous results
564 were observed in our study: gestational BPA exposure significantly disrupted the
565 redox balance and promoted inflammatory responses in maternal serum and placental
566 tissues. Specifically, the activity of SOD, a key antioxidant enzyme, was markedly
567 decreased in serum and placental tissues, the level of MDA, a lipid peroxidation
568 product, was significantly elevated in serum, and the level of the proinflammatory
569 cytokine *IL-6* was also notably increased in both serum and placental tissues. In
570 contrast, taurine supplementation effectively reversed these BPA-induced
571 abnormalities by significantly upregulating SOD activity in serum and placenta to
572 enhance antioxidant defense capacity, downregulating serum MDA levels to alleviate
573 oxidative damage, and simultaneously reducing the levels of the proinflammatory
574 cytokines *IL-6*, *IL-1 β* and *TNF- α* in serum. These results suggested that taurine can
575 break the “oxidative stress-inflammation” vicious cycle via inhibiting oxidative stress
576 and alleviating aberrant inflammatory responses.

577 To further elucidate the molecular mechanisms underlying taurine-mediated
578 antagonism of oxidative stress and attenuation of inflammatory responses, the present
579 study focused on analyses of the core regulatory Nrf2-Keap1 pathway and the



580 modulation of proinflammatory cytokines. The Nrf2 signaling pathway serves as the
581 central cellular pathway for regulating oxidative stress and plays a pivotal role in
582 maintaining redox homeostasis in the organism³⁸. Under physiological conditions,
583 Nrf2 forms an inactive complex with Keap1 in the cytoplasm; upon exposure to
584 oxidative stress stimuli, the Nrf2-Keap1 complex dissociates, and free Nrf2
585 translocates into the nucleus, where it binds to antioxidant response elements (AREs)
586 to activate the transcriptional expression of various downstream antioxidant enzyme
587 genes. This process enhances the organism's antioxidant capacity, thereby scavenging
588 excessive reactive oxygen species (ROS) and restoring redox homeostasis^{39, 40}.
589 Accumulating evidence has confirmed that BPA exposure induces oxidative stress
590 damage in multiple tissues by inhibiting the activation of the Nrf2-Keap1 pathway
591 and downregulating the expression of antioxidant genes³⁷, whereas taurine exerts
592 antioxidant protective effects by activating the Nrf2-Keap1 pathway¹⁶. As a critical
593 interface for material exchange between the mother and fetus, the placenta's redox
594 and inflammatory homeostasis, along with its normal physiological function, are
595 essential for sustaining normal fetal development. In this study, gestational BPA
596 exposure significantly inhibited the mRNA expression of Nrf2 in placental tissue,
597 while markedly upregulating the expression of its negative regulator Keap1 and the
598 downstream target gene *NQO1*, and significantly downregulating the transcriptional
599 levels of key downstream antioxidant enzymes (*CAT*, *SOD1*). These changes led to a
600 decline in placental antioxidant capacity and exacerbated oxidative stress damage. In
601 contrast, taurine supplementation significantly upregulated the mRNA expression of
602 *Nrf2* in placental tissue, suppressed the overexpression of *Keap1*, and simultaneously
603 enhanced the transcriptional levels of downstream antioxidant enzymes (*CAT*, *SOD1*,
604 *SOD2*). These results demonstrate that taurine enhances the antioxidant defense
605 capacity of placental tissue by activating the Nrf2-Keap1 signaling pathway and
606 upregulating the expression of downstream antioxidant genes, thereby effectively
607 alleviating BPA-induced placental oxidative stress damage—consistent with previous
608 findings that taurine exerts antioxidant protection via modulation of the Nrf2-Keap1
609 pathway^{41, 42}. Inflammatory responses and oxidative stress often act synergistically:



610 BPA-induced placental oxidative stress can further activate inflammatory signaling
611 pathways, and aberrant inflammatory responses can in turn exacerbate oxidative stress
612 damage. Together, these two processes compound placental dysfunction. The present
613 study also found that BPA exposure induced a robust proinflammatory response in
614 placental tissue, significantly upregulating the mRNA expression of the
615 proinflammatory cytokines *IL-6*, *IL-8*, and *IL-1 β* in placental tissue. In contrast,
616 taurine supplementation significantly reduced the overexpression of these
617 proinflammatory cytokines and exhibited a trend toward upregulating the expression
618 of the anti-inflammatory cytokine *IL-10*. These findings indicate that taurine
619 rebalances the placental inflammatory microenvironment by inhibiting
620 proinflammatory factor expression and promoting anti-inflammatory factor secretion,
621 thereby alleviating inflammation-mediated placental damage and exerting a
622 synergistic effect with its antioxidant properties.

623 BPA-induced placental oxidative stress and inflammatory responses can further
624 impair placental nutrient transport function, a pathological process closely associated
625 with the downregulated expression of key placental functional genes. Syncytin B
626 (SynB) is a critical syncytin involved in the formation of the trophoblast layer at the
627 maternal-fetal interface of the mouse placenta and plays an essential role in fetal
628 material exchange ⁴³. Previous studies have reported that SynB deficiency leads to
629 placental dysfunction, which in turn causes embryonic growth retardation and reduced
630 neonatal survival rates ⁴⁴. Insulin-like growth factor 2 (IGF2) is a key regulator of
631 fetal nutrient supply and exerts a vital role in the normal functional development of
632 the mouse placenta; it maintains placental nutrient transport function by regulating the
633 proliferation and differentiation of placental trophoblast cells ⁴⁵. Moreover, IGF2
634 deficiency in the placenta impairs the maternal insulin resistance response, leading to
635 fetal growth restriction and further affecting postnatal metabolic function in offspring
636 ⁴⁶. Our findings demonstrated that BPA exposure significantly downregulated the
637 mRNA expression of *SynB* and *IGF2* in placental tissue, indicating that BPA impairs
638 placental nutrient transport function by inhibiting the expression of functional genes
639 related to placental nutrient transport, thereby resulting in impaired fetal growth and



640 development and reduced birth weight. In contrast, taurine supplementation
641 effectively reversed these abnormalities and markedly upregulated the mRNA
642 expression of *SynB* and *IGF2*. These results suggest that taurine not only alleviates
643 placental damage by inhibiting oxidative stress and rebalancing the inflammatory
644 microenvironment, but also ensures material exchange and nutrient supply between
645 the mother and fetus by restoring the expression of key functional genes associated
646 with placental nutrient transport, thus providing critical support for normal fetal
647 growth and development.

648 The liver, as the body's core detoxification organ and metabolic hub, is critical
649 for maintaining systemic metabolic homeostasis and eliminating exogenous toxicants.
650 The normal functioning of hepatic function during pregnancy not only safeguards
651 maternal health per se but also exerts a pivotal role in fetal metabolic development.
652 Accumulating evidence has indicated that direct BPA exposure or indirect exposure
653 following maternal ingestion can reduce *Nrf2* expression in the liver of male offspring
654 rats, thereby exacerbating hepatic oxidative stress and inducing liver injury⁴⁷. The
655 findings of the present study further confirm that BPA exposure similarly disrupts the
656 oxidative stress balance and aggravates inflammatory responses in the maternal and
657 fetal livers. The antioxidant and anti-inflammatory regulatory effects of taurine in the
658 placenta are consistent with those observed in the maternal and fetal livers: excessive
659 hepatic oxidative stress induced by BPA can inhibit Nrf2-mediated antioxidant
660 responses, whereas taurine alleviates BPA-induced hepatic oxidative damage by
661 activating the Nrf2 signaling pathway and upregulating the expression of antioxidant
662 genes.

663 Consistent with previous findings³⁷, the present study confirmed that
664 BPA-induced liver injury is mediated by the synergistic effects of oxidative stress and
665 inflammatory responses. Furthermore, our results further demonstrated that taurine
666 supplementation can significantly activate the expression of key factors in the Nrf2
667 signaling pathway and simultaneously inhibit the overexpression of proinflammatory
668 factors in both maternal and fetal livers, exerting a systemic hepatoprotective effect.
669 In the fetal liver, taurine specifically suppressed BPA-induced overexpression of *IL-8*



670 and *TNF- α* and upregulated the expression level of *SOD2*, effectively alleviating
671 hepatic inflammation and oxidative damage to ensure the normal development of the
672 fetal liver. In the maternal liver, taurine not only activated the Nrf2-Keap1 pathway
673 and inhibited the expression of the proinflammatory factors *IL-6* and *IL-1 β* , but also
674 significantly upregulated the transcriptional level of peroxisome proliferator-activated
675 receptor γ (*PPAR γ*). As a nuclear receptor, *PPAR γ* mediates the bidirectional
676 regulation of inflammatory responses and redox homeostasis either by directly
677 binding to the promoters of target genes or through protein-protein interactions with
678 signaling molecules such as NF- κ B and Nrf2^{48, 49}, which contributes to the
679 coordinated regulation of inflammatory responses and the maintenance of
680 homeostasis in maternal hepatic detoxification and metabolic functions. These results
681 are consistent with previous reports that taurine alleviates liver injury induced by
682 various toxic substances via its antioxidant and anti-inflammatory properties⁵⁰.

683 Furthermore, as the primary organ for bile acid synthesis, the liver's BA
684 metabolic homeostasis directly modulates maternal nutrient absorption and
685 detoxification functions. Our study found that taurine supplementation significantly
686 upregulated the mRNA expression of *CYP27A1*; as a key rate-limiting enzyme in BA
687 synthesis, the upregulated expression of *CYP27A1* enhances BA synthetic capacity,
688 which contributes to the maintenance of BA metabolic homeostasis. These results
689 further confirm that taurine preserves BA metabolic homeostasis by activating the
690 Nrf2-Keap1 signaling pathway and rebalancing the inflammatory microenvironment,
691 thereby exerting a systemic protective effect on maternal and fetal livers. In turn, this
692 maintains the metabolic homeostasis of the maternal-fetal unit and provides a
693 favorable internal environment for fetal growth and development.

694 The gut microbiota, as a core component of the body's microecological system,
695 directly regulates nutrient metabolism and immune homeostasis between the mother
696 and fetus via the gut-placental axis, and serves as a critical microecological
697 foundation for ensuring normal fetal development⁵¹. Dysbiosis of the maternal gut
698 microbiota induces fetal metabolic abnormalities and immune developmental
699 disorders, ultimately increasing the risk of adverse pregnancy outcomes such as fetal



700 growth restriction^{52, 53}. The findings of the present study demonstrated that BPA
701 exposure significantly reduced the α -diversity index of the maternal murine gut
702 microbiota, altered the microbial community structure, and markedly increased the
703 Firmicutes/Bacteroidetes (F/B) ratio, severely disrupting the homeostasis of the
704 maternal gut microbiota. These results are consistent with previous reports that BPA
705 exposure reduces gut microbial diversity in animals, and our study is the first to
706 confirm the association of this effect with hormonal regulatory network dysregulation
707 in a pregnancy model. Taurine supplementation significantly reversed the
708 aforementioned abnormal indices, indicating its ability to effectively restore microbial
709 diversity and maintain gut microecological homeostasis during the unique
710 physiological stage of pregnancy.

711 Further analysis revealed that taurine supplementation alleviates BPA-induced
712 specific dysbiosis of *norank_f_Muribaculaceae*, *Ruminococcus* and *Bifidobacterium*.
713 As a core beneficial bacterial family within the phylum Bacteroidetes,
714 *Muribaculaceae* produces short-chain fatty acids (SCFAs) via the fermentation of
715 dietary fiber and endogenous mucin glycans⁵⁴, and also participates in intestinal
716 barrier maintenance and mucin metabolism regulation⁵⁵, serving as a key biomarker
717 of intestinal homeostasis. In the present study, BPA exposure significantly
718 downregulated the abundance of *Muribaculaceae*, which may lead to a reduction in
719 SCFA synthesis capacity and impairment of intestinal barrier integrity, thereby
720 exacerbating inflammatory responses—an observation consistent with the decreased
721 abundance of *Muribaculaceae* reported in models of inflammatory bowel disease
722 (IBD) and type 2 diabetes (T2D)-associated metabolic disorders^{56, 57}. In contrast,
723 taurine supplementation markedly upregulated the abundance of
724 *norank_f_Muribaculaceae*; by restoring SCFA synthetic function and intestinal
725 barrier maintenance capacity, taurine inhibits aberrant inflammatory responses,
726 enhances intestinal barrier integrity, and thereby exerts a protective effect.
727 Concomitantly, the restored abundance of *norank_f_Muribaculaceae* promotes the
728 renewal and thickening of the intestinal mucus layer, which further consolidates the
729 intestinal physical barrier and creates a favorable microenvironment for the



730 colonization and proliferation of other beneficial bacteria.

View Article Online
DOI: 10.1039/D6FO00521G

731 Furthermore, taurine reverses BPA-induced over-enrichment of *Bifidobacterium*
732 and inhibition of *Ruminococcus*. As a classic probiotic genus, *Bifidobacterium* is
733 significantly upregulated upon BPA exposure, and this response represents a
734 compensatory proliferation following microbial dysbiosis rather than a beneficial
735 adaptive reaction. Such excessive proliferation disrupts the competitive balance of the
736 gut microbiota and consequently exacerbates microecological disorder, a phenomenon
737 that may be associated with microbial metabolic abnormalities induced by BPA
738 exposure. In contrast, taurine supplementation effectively suppresses the aberrant
739 proliferation of *Bifidobacterium*, restoring its abundance to physiological levels and
740 thus facilitating the re-establishment of microbial homeostasis. *Ruminococcus*, a core
741 functional genus within the phylum Firmicutes that modulates BA metabolism,
742 maintains host BA metabolic homeostasis by mediating BA transformation and the
743 enterohepatic circulation. *Ruminococcus torques*, a strain of this genus closely linked
744 to intestinal inflammation, elicits insufficient synthesis of secondary BAs when its
745 abundance is imbalanced; this deficiency disrupts intestinal immune homeostasis and
746 promotes the initiation and progression of inflammatory responses⁵⁸. This study
747 further confirms that the reduced abundance of *Ruminococcus* induced by BPA
748 exposure is not merely a disruption of microbial community structure, but a core
749 trigger for the imbalance of the microbiota-BA metabolism axis. Functional
750 prediction analysis revealed that BPA exposure concurrently elicits bidirectional
751 dysregulation of BA metabolism-related pathways, significantly downregulating the
752 gene expression of the BA sodium symporter (BASS) family and aberrantly
753 upregulating the functional activity of 7 α -hydroxysteroid dehydrogenase (7 α -HSDH).
754 The BASS family proteins mediate the intestinal absorption and transport of BAs; the
755 inhibition of their pathway expression directly impairs the integrity of the BA
756 enterohepatic circulation and disrupts the physiological balance of the intestinal BA
757 pool. As a key rate-limiting enzyme catalyzing the conversion of primary BAs to
758 secondary BAs, the non-physiological elevation of 7 α -HSDH activity leads to an
759 imbalance in the conversion ratio of secondary BAs, driving the excessive



760 accumulation of toxic BAs such as lithocholic acid and further exacerbating
761 inflammatory responses. In contrast, taurine can target the restoration of
762 *Ruminococcus* abundance, significantly reduce the abnormally elevated 7 α -HSDH
763 activity in the intestine, further repair the microbiota-mediated BA metabolic function,
764 and reverse BPA-induced metabolic disorders.

765 Targeted metabolomic analysis further validated the dysregulation of the
766 microbiota-BA regulatory axis and the reparative effects of taurine on this
767 pathological process. BPA exposure significantly downregulated the concentrations of
768 conjugated BAs (including GCA, TCA and TCDCA) and total tauro-conjugated bile
769 acids (Total-TCBA), while concomitantly inducing an abnormal elevation in
770 apocholic acid (ACA) levels. This metabolic profile was consistent with the
771 functional prediction results of reduced *Ruminococcus* abundance, upregulated
772 7 α -HSDH activity and downregulated BASS family expression. The decreased serum
773 levels of conjugated BAs resulted from the combined effects of impaired synthesis
774 and defective transport. More importantly, the synthesis of Total-TCBA requires
775 taurine as an essential precursor, and maternal metabolic disorders induced by BPA
776 exposure may indirectly inhibit the de novo synthesis and utilization of endogenous
777 taurine, which further exacerbates the insufficient production of Total-TCBA. The
778 abnormal elevation of ACA may further aggravate oxidative stress and inflammatory
779 damage in maternal and fetal tissues by activating proinflammatory signaling
780 pathways. Additionally, our correlation analysis further confirmed that aberrant
781 alterations in BA components can amplify BPA-induced toxicity through oxidative
782 stress and inflammatory pathways. This finding indicates that BA metabolic
783 dysregulation can directly disrupt maternal-fetal immune homeostasis, trigger
784 oxidative stress damage, and exacerbate local and systemic inflammatory responses.
785 Notably, taurine exerts its BA-modulating effects through a dual mechanism: on the
786 one hand, exogenous taurine supplementation provides an abundant precursor for the
787 synthesis of Total-TCBA and simultaneously targets the regulation of gut microbiota
788 and metabolic pathways, which synergistically mitigates the decline in Total-TCBAs
789 and exerts a positive effect on elevating the concentrations of conjugated BAs and



790 Total-TCBAs; on the other hand, it significantly suppresses the accumulation of BAs
791 such as ACA and LCA, and blocks the proinflammatory and oxidative stress
792 pathways mediated by these BAs. Although some indicators have not been fully
793 restored to the levels of the control group, taurine has significantly ameliorated
794 BPA-induced BA metabolic dysregulation, thereby providing crucial metabolic
795 support for its antagonism of BPA-induced maternal-fetal toxicity. Though taurine is
796 a key precursor of TCBA that promotes BA synthesis, total TCBA levels were not
797 significantly restored in the BPA+Tau group, likely due to systemic hepatic BA
798 metabolic disruption (impaired synthetic enzymes, transport and enterohepatic
799 circulation) induced by BPA exposure, which taurine only partially alleviates.
800 Notably, taurine still significantly regulated specific TCBA subtypes and corrected
801 BPA-induced BA profile imbalance, the core of its protective effect against
802 maternal-fetal toxicity. The marginal increasing trend of total TCBA in the BPA+Tau
803 group ($0.05 \leq P < 0.10$) also suggests that a larger sample size may verify the
804 restorative effect of taurine on total TCBA levels in future studies.

805 In summary, taurine potently reverses the BPA-induced imbalance of the
806 microbiota-BA-oxidative stress/inflammation axis, effectively antagonizes
807 BPA-elicited maternal-fetal damage, and preserves maternal-fetal microecological
808 and metabolic homeostasis (**Fig. 9**).

809 **Conclusion**

810 This study confirms that taurine can effectively alleviate BPA-induced maternal-fetal
811 oxidative stress by targeting the “gut microbiota-BA-oxidative stress/inflammation”
812 axis, protect liver and placental functions, and improve intestinal microbiota
813 imbalance and BA metabolism disorders. Through multi-dimensional synergistic
814 regulation, taurine comprehensively ensures the nutritional absorption and metabolic
815 development of the fetus, and ultimately reverses the fetal weight loss and adverse
816 pregnancy outcomes caused by BPA. As a safe and non-toxic conditionally essential
817 amino acid, taurine is expected to become a potential candidate for preventing and
818 intervening in maternal-fetal toxicity caused by BPA exposure. This study not only



819 clarifies the intrinsic mechanism of taurine antagonizing BPA-induced maternal-fetal
820 toxicity, but also provides new ideas and theoretical references for maintaining
821 maternal-fetal health during pregnancy and promoting normal fetal development.

822 **Author contributions**

823 Conceptualization, Yu Pi. and Xilong Li. and Chenggang Yin.; methodology, Yu Pi.
824 and Xilong Li. and Wenjuan Sun.; validation, Yu Pi. and Xilong Li. and Yanpin Li.;
825 formal analysis, Chenggang Yin. and Lei Xu. and Yuyang Fan.; investigation,
826 Chenggang Yin. and Lei Xu. and Jiaqi Yang.; data curation, Chenggang Yin. and Lei
827 Xu.; writing—original draft preparation, Lei Xu.; writing—review and editing, Yu Pi.
828 and Xilong Li. and Yanpin Li. and Dongxu Ming.; supervision, Yu Pi. and Xilong Li.;
829 project administration, Yu Pi. and Yanpin Li.; funding acquisition, Yu Pi. and Xilong
830 Li. All authors have read and agreed to the published version of the manuscript.

831 **Data availability statement**

832 All data used for this study appear in the illustrated figures, and the raw data will
833 promptly be made available upon request.

834 **Conflicts of interest**

835 The authors report no conflicts of interest. The authors alone are responsible for the
836 content and writing of this article.

837 **Acknowledgments**

838 This research was funded by the National Natural Science Foundation of China
839 (32573250) and the Agricultural Science and Technology Innovation Program of the
840 Feed Research Institute of the Chinese Academy of Agricultural Sciences
841 (CAAS-IFR-ZDRW202402 and CAAS-ASTIP-2023-IFR-12).

842



844 **References**

- 845 1. S. Almeida, A. Raposo, M. Almeida-González and C. Carrascosa, Bisphenol A: Food
846 Exposure and Impact on Human Health, 2018, **17**, 1503-1517.
- 847 2. J. R. Rochester, Bisphenol A and human health: A review of the literature, *Reproductive*
848 *Toxicology*, 2013, **42**, 132-155.
- 849 3. G. Schönfelder, W. Wittfoht, H. Hopp, C. E. Talsness, M. Paul and I. Chahoud, Parent
850 bisphenol A accumulation in the human maternal-fetal-placental unit, *Environmental health*
851 *perspectives*, 2002, **110**, A703-707.
- 852 4. M. S. Nahar, C. Liao, K. Kannan, D. C. J. J. o. b. Dolinoy and m. toxicology, Fetal liver
853 bisphenol A concentrations and biotransformation gene expression reveal variable exposure
854 and altered capacity for metabolism in humans, 2013, **27**, 116-123.
- 855 5. S. A. Krieg, L. K. Shahine and R. B. Lathi, Environmental exposure to endocrine-disrupting
856 chemicals and miscarriage, *Fertility and sterility*, 2016, **106**, 941-947.
- 857 6. C. Philippat, M. Mortamais, C. Chevrier, C. Petit, A. M. Calafat, X. Ye, M. J. Silva, C.
858 Brambilla, I. Pin, M. A. Charles, S. Cordier and R. Slama, Exposure to phthalates and phenols
859 during pregnancy and offspring size at birth, *Environmental health perspectives*, 2012, **120**,
860 464-470.
- 861 7. F. Fischer, T. Kretschmer, P. Seifert, J. Howanski, E. Krieger, J. Rödiger, B. Fink, Z. Yin, M.
862 Bauer, M. L. Zenclussen, N. Meyer, A. Schumacher and A. C. Zenclussen, Single and
863 combined exposures to bisphenol A and benzophenone-3 during early mouse pregnancy have
864 differential effects on fetal and placental development, *The Science of the total environment*,
865 2024, **922**, 171386.
- 866 8. D. Yan, Y. Jiao, H. Yan, T. Liu, H. Yan and J. Yuan, Endocrine-disrupting chemicals and the
867 risk of gestational diabetes mellitus: a systematic review and meta-analysis, *Environmental*
868 *health : a global access science source*, 2022, **21**, 53.
- 869 9. O. Takahashi and S. J. E. h. p. Oishi, Disposition of orally administered 2, 2-Bis
870 (4-hydroxyphenyl) propane (Bisphenol A) in pregnant rats and the placental transfer to fetuses,
871 2000, **108**, 931.
- 872 10. J. E. Müller, N. Meyer, C. G. Santamaria, A. Schumacher, E. H. Luque, M. L. Zenclussen, H.
873 A. Rodriguez and A. C. Zenclussen, Bisphenol A exposure during early pregnancy impairs
874 uterine spiral artery remodeling and provokes intrauterine growth restriction in mice,
875 *Scientific Reports*, 2018, **8**, 9196.
- 876 11. H. Kabuto, M. Amakawa and T. Shishibori, Exposure to bisphenol A during embryonic/fetal
877 life and infancy increases oxidative injury and causes underdevelopment of the brain and testis
878 in mice, *Life Sciences*, 2004, **74**, 2931-2940.
- 879 12. A. B. Javurek, W. G. Spollen, S. A. Johnson, N. J. Bivens, K. H. Bromert, S. A. Givan and C.
880 S. Rosenfeld, Effects of exposure to bisphenol A and ethinyl estradiol on the gut microbiota of
881 parents and their offspring in a rodent model, *Gut microbes*, 2016, **7**, 471-485.
- 882 13. H. Zhang, X. Zha, B. Zhang, Y. Zheng, M. Elsabagh, H. Wang and M. Wang, Gut microbiota
883 contributes to bisphenol A-induced maternal intestinal and placental apoptosis, oxidative
884 stress, and fetal growth restriction in pregnant ewe model by regulating gut-placental axis,
885 *Microbiome*, 2024, **12**, 28.
- 886 14. C. Wen, F. Li, L. Zhang, Y. Duan, Q. Guo, W. Wang, S. He, J. Li and Y. Yin, Taurine is
887 Involved in Energy Metabolism in Muscles, Adipose Tissue, and the Liver, *Molecular*



- 888 *nutrition & food research*, 2019, **63**, e1800536.
- 889 15. B. N. Ames, Prolonging healthy aging: Longevity vitamins and proteins, *Proceedings of the*
890 *National Academy of Sciences of the United States of America*, 2018, **115**, 10836-10844.
- 891 16. X. Ji, Z. Tang, F. Zhang, F. Zhou, Y. Wu and D. Wu, Dietary taurine supplementation
892 counteracts deoxynivalenol-induced liver injury via alleviating oxidative stress, mitochondrial
893 dysfunction, apoptosis, and inflammation in piglets, *Ecotoxicology and Environmental Safety*,
894 2023, **253**, 114705.
- 895 17. D. D. Zhao, J. J. Wang, J. J. Fan, Y. Fu, Y. D. Ma, C. Li, G. F. Wu, M. Liu, S. M. Lin and J.
896 M. Hu, Taurine Prevents LPS-Induced Liver Injury in Weaned Piglets, *Advances in*
897 *experimental medicine and biology*, 2022, **1370**, 497-505.
- 898 18. S. Tochitani, Functions of Maternally-Derived Taurine in Fetal and Neonatal Brain
899 Development, *Advances in experimental medicine and biology*, 2017, **975 Pt 1**, 17-25.
- 900 19. J. A. Sturman, D. K. Rassin and G. E. Gaull, Taurine in developing rat brain: maternal-fetal
901 transfer of [³⁵S] taurine and its fate in the neonate, *Journal of neurochemistry*, 1977, **28**,
902 31-39.
- 903 20. M. M. Ommati, H. Rezaei, R.-M. Socorro, W. Tian, J. Zhao, A. Rouhani, S. Sabouri, F.
904 Ghaderi, A. M. Niknahad, A. Najibi, S. Mazloomi, M. Safipour, Z. Honarpishefard, H.-W.
905 Wang, H. Niknahad and R. Heidari, Pre/postnatal taurine supplementation improves
906 neurodevelopment and brain function in mice offspring: A persistent developmental study
907 from puberty to maturity, *Life Sciences*, 2024, **336**, 122284.
- 908 21. M. Li, C. M. Reynolds, D. M. Sloboda, C. Gray and M. H. Vickers, Maternal taurine
909 supplementation attenuates maternal fructose-induced metabolic and inflammatory
910 dysregulation and partially reverses adverse metabolic programming in offspring, *The Journal*
911 *of nutritional biochemistry*, 2015, **26**, 267-276.
- 912 22. J. J. P. o. t. S. f. E. B. Sjövall and Medicine, Dietary glycine and taurine on bile acid
913 conjugation in man. Bile acids and steroids 75, 1959, **100**, 676-678.
- 914 23. W. G. J. G. Hardison, Hepatic taurine concentration and dietary taurine as regulators of bile
915 acid conjugation with taurine, 1978, **75**, 71-75.
- 916 24. K. Duszka, Versatile Triad Alliance: Bile Acid, Taurine and Microbiota, 2022, **11**, 2337.
- 917 25. J.-Y. Yang, T.-T. Zhang, Z.-L. Yu, C.-C. Wang, Y.-C. Zhao, Y.-M. Wang, C.-H. J. J. o. A.
918 Xue and F. Chemistry, Taurine alleviates trimethylamine N-oxide-induced atherosclerosis by
919 regulating bile acid metabolism in ApoE^{-/-}mice, 2022, **70**, 5738-5747.
- 920 26. J. Münzker, N. Haase, A. Till, R. Sucher, S.-B. Haange, L. Nemetschke, T. Gnad, E. Jäger, J.
921 Chen, S. J. Riede, R. Chakaroun, L. Massier, P. Kovacs, M. Ost, U. Rolle-Kampczyk, N.
922 Jehmlich, J. Weiner, J. T. Heiker, N. Klötting, G. Seeger, M. Morawski, V. Keitel, A. Pfeifer,
923 M. von Bergen, J. Heeren, U. Krügel and W. K. Fenske, Functional changes of the gastric
924 bypass microbiota reactivate thermogenic adipose tissue and systemic glucose control via
925 intestinal FXR-TGR5 crosstalk in diet-induced obesity, *Microbiome*, 2022, **10**, 96.
- 926 27. H. Wang, Y. Guo, W. Han, M. Liang, X. Xiao, X. Jiang, W. J. J. o. a. Yu and f. chemistry,
927 Tauroursodeoxycholic acid improves nonalcoholic fatty liver disease by regulating gut
928 microbiota and bile acid metabolism, 2024, **72**, 20194-20210.
- 929 28. N. A. Mohamed, M. T. Ithmil, A. I. Elkady and S. Abdel Salam, Tauroursodeoxycholic Acid
930 (TUDCA) Relieves Streptozotocin (STZ)-Induced Diabetic Rat Model via Modulation of
931 Lipotoxicity, Oxidative Stress, Inflammation, and Apoptosis, 2024, **25**, 6922.



- 932 29. P. Singh, K. Gollapalli, S. Mangiola, D. Schraner, M. A. Yusuf, M. Chamoli, S. L. Shi, B. View Article Online
DOI: 10.1039/D6FO00521G
933 Lopes Bastos, T. Nair and A. Riermeier, Taurine deficiency as a driver of aging, *Science*,
934 2023, **380**, eabn9257.
- 935 30. Y. Sun, M. Sha, Y. Qin, J. Xiao, W. Li, S. Li and S. Chen, Bisphenol A induces placental
936 ferroptosis and fetal growth restriction via the YAP/TAZ-ferritinophagy axis, *Free Radical*
937 *Bio Med*, 2024, **213**, 524-540.
- 938 31. M. Janot, M. L. Cortes-Dubly, S. Rodriguez and U. Huynh-Do, Bilateral uterine vessel
939 ligation as a model of intrauterine growth restriction in mice, *Reproductive biology and*
940 *endocrinology : RB&E*, 2014, **12**, 62.
- 941 32. Y. Pi, Y. J. Wu, X. Y. Zhang, D. D. Lu, D. D. Han, J. C. Zhao, X. J. Zheng, S. Y. Zhang, H.
942 Ye, S. Lian, Y. Bai, Z. Y. Wang, S. Y. Tao, D. J. Ni, X. H. Zou, W. Jia, G. L. Zhang, D. F. Li
943 and J. J. Wang, Gut microbiota-derived ursodeoxycholic acid alleviates low birth
944 weight-induced colonic inflammation by enhancing M2 macrophage polarization, *Microbiome*,
945 2023, **11**.
- 946 33. C. Yin, L. Xu, Z. Wei, Y. Zhao, R. Bai, G. Gao, Y. Fan, Y. Li, W. Sun, X. Li and Y. Pi, Gut
947 microbiota and bile acid profiles in purebred vs. crossbred sows: links to oxidative stress and
948 inflammation in late gestation, *Microbial genomics*, 2025, **11**.
- 949 34. Y. Pi, X. Y. Zhang, Y. J. Wu, Z. Y. Wang, Y. Bai, X. Y. Liu, D. D. Han, J. B. Zhao, I. Tobin,
950 J. C. Zhao, G. L. Zhang and J. J. Wang, Alginate Alleviates Dextran Sulfate Sodium-Induced
951 Colitis by Promoting Bifidobacterium animalis and Intestinal Hyodeoxycholic Acid Synthesis
952 in Mice, *Microbiology spectrum*, 2022, **10**.
- 953 35. Y. F. Huang, P. W. Wang, L. W. Huang, C. H. Lai, W. Yang, K. Y. Wu, C. A. Lu, H. C. Chen
954 and M. L. Chen, Prenatal Nonylphenol and Bisphenol A Exposures and Inflammation Are
955 Determinants of Oxidative/Nitrative Stress: A Taiwanese Cohort Study, *Environmental*
956 *science & technology*, 2017, **51**, 6422-6429.
- 957 36. K. K. Ferguson, D. E. Cantonwine, T. F. McElrath, B. Mukherjee and J. D. Meeker, Repeated
958 measures analysis of associations between urinary bisphenol-A concentrations and biomarkers
959 of inflammation and oxidative stress in pregnancy, *Reproductive toxicology (Elmsford, N.Y.)*,
960 2016, **66**, 93-98.
- 961 37. B. Linillos-Pradillo, L. Rancan, S. D. Paredes, M. Schlumpf, W. Lichtensteiger, E. Vara and J.
962 Á. F. Tresguerres, Low Dose of BPA Induces Liver Injury through Oxidative Stress,
963 Inflammation and Apoptosis in Long-Evans Lactating Rats and Its Perinatal Effect on Female
964 PND6 Offspring, 2023, **24**, 4585.
- 965 38. T. Suzuki, J. Takahashi and M. Yamamoto, Molecular Basis of the KEAP1-NRF2 Signaling
966 Pathway, *Molecules and cells*, 2023, **46**, 133-141.
- 967 39. S. Adinolfi, T. Patinen, A. Jawahar Deen, S. Pitkänen, J. Härkönen, E. Kansanen, J. Küblbeck
968 and A. L. Levonen, The KEAP1-NRF2 pathway: Targets for therapy and role in cancer,
969 *Redox biology*, 2023, **63**, 102726.
- 970 40. M. Yamamoto, T. W. Kensler and H. Motohashi, The KEAP1-NRF2 System: a Thiol-Based
971 Sensor-Effector Apparatus for Maintaining Redox Homeostasis, *Physiological reviews*, 2018,
972 **98**, 1169-1203.
- 973 41. G. Wu, J. San, H. Pang, Y. Du, W. Li, X. Zhou, X. Yang, J. Hu and J. Yang, Taurine
974 attenuates AFB1-induced liver injury by alleviating oxidative stress and regulating
975 mitochondria-mediated apoptosis, *Toxicon : official journal of the International Society on*



- 976 *Toxinology*, 2022, **215**, 17-27.
- 977 42. C. Chen, M. Qi, W. Zhang, F. Chen, Z. Sun, W. Sun, W. Tang, Z. Yang, X. Zhao and Z. Tang,
- 978 Taurine alleviated paraquat-induced oxidative stress and gut-liver axis damage in weaned
- 979 piglets by regulating the Nrf2/Keap1 and TLR4/NF- κ B signaling pathways, *Journal of animal*
- 980 *science and biotechnology*, 2025, **16**, 117.
- 981 43. G. Mousseau, N. Pr  ault, S. Souquere, C. Bireau, P. Cassonnet, A. Bacquin, L. Beck, G.
- 982 Pierron, Y. Jacob, A. Dupressoir and T. Heidmann, Sodium-dependent phosphate transporter
- 983 PiT1/SLC20A1 as the receptor for the endogenous retroviral envelope syncytin-B involved in
- 984 mouse placenta formation, *Journal of virology*, 2024, **98**, e0091524.
- 985 44. A. Dupressoir, C. Vernochet, F. Harper, J. Gu  gan, P. Dessen, G. Pierron and T. Heidmann, A
- 986 pair of co-opted retroviral envelope syncytin genes is required for formation of the
- 987 two-layered murine placental syncytiotrophoblast, *Proceedings of the National Academy of*
- 988 *Sciences of the United States of America*, 2011, **108**, E1164-1173.
- 989 45. C. P. Sibley, P. M. Coan, A. C. Ferguson-Smith, W. Dean, J. Hughes, P. Smith, W. Reik, G. J.
- 990 Burton, A. L. Fowden and M. Const  ncia, Placental-specific insulin-like growth factor 2 (Igf2)
- 991 regulates the diffusional exchange characteristics of the mouse placenta, *Proceedings of the*
- 992 *National Academy of Sciences of the United States of America*, 2004, **101**, 8204-8208.
- 993 46. J. Lopez-Tello, H. E. J. Yong, I. Sandovici, G. K. C. Dowsett, E. R. Christoforou, E.
- 994 Salazar-Petres, R. Boyland, T. Napso, G. S. H. Yeo, B. Y. H. Lam, M. Constancia and A. N.
- 995 Sferruzzi-Perri, Fetal manipulation of maternal metabolism is a critical function of the
- 996 imprinted Igf2 gene, *Cell metabolism*, 2023, **35**, 1195-1208.e1196.
- 997 47. J.-X. Liao, Y.-W. Chen, M.-K. Shih, Y.-L. Tain, Y.-T. Yeh, M.-H. Chiu, S. K. C. Chang and
- 998 C.-Y. Hou, Resveratrol Butyrate Esters Inhibit BPA-Induced Liver Damage in Male Offspring
- 999 Rats by Modulating Antioxidant Capacity and Gut Microbiota, 2021, **22**, 5273.
- 1000 48. M. Fang, Q. Yu, J. Ou, J. Lou, J. Zhu and Z. Lin, The Neuroprotective Mechanisms of
- 1001 PPAR- γ : Inhibition of Microglia-Mediated Neuroinflammation and Oxidative Stress in a
- 1002 Neonatal Mouse Model of Hypoxic-Ischemic White Matter Injury, *CNS neuroscience &*
- 1003 *therapeutics*, 2024, **30**, e70081.
- 1004 49. W. Cai, T. Yang, H. Liu, L. Han, K. Zhang, X. Hu, X. Zhang, K. J. Yin, Y. Gao, M. V. L.
- 1005 Bennett, R. K. Leak and J. Chen, Peroxisome proliferator-activated receptor γ (PPAR γ): A
- 1006 master gatekeeper in CNS injury and repair, *Progress in neurobiology*, 2018, **163-164**, 27-58.
- 1007 50. G. Ouyang, N. Wang, J. Tong, W. Sun, J. Yang and G. Wu, Alleviation of taurine on liver
- 1008 injury of type 2 diabetic rats by improving antioxidant and anti-inflammatory capacity,
- 1009 *Heliyon*, 2024, **10**, e28400.
- 1010 51. D. Kelly, T. King and R. Aminov, Importance of microbial colonization of the gut in early life
- 1011 to the development of immunity, *Mutation research*, 2007, **622**, 58-69.
- 1012 52. M. Levy, A. A. Kolodziejczyk, C. A. Thaiss and E. Elinav, Dysbiosis and the immune system,
- 1013 *Nature reviews. Immunology*, 2017, **17**, 219-232.
- 1014 53. S. Giugliano, A. Gatti, M. Rusin, T. Schorn, S. Pimazzoni, M. Calanni-Pileri, V. Fraccascia, S.
- 1015 Carloni and M. Rescigno, Maternal gut microbiota influences immune activation at the
- 1016 maternal-fetal interface affecting pregnancy outcome, *Nature communications*, 2025, **16**,
- 1017 4326.
- 1018 54. C. Xu, J. Liu, J. Gao, X. Wu, C. Cui, H. Wei, R. Zheng and J. Peng, Combined Soluble
- 1019 Fiber-Mediated Intestinal Microbiota Improve Insulin Sensitivity of Obese Mice, *Nutrients*,



- 1020 2020, **12**. View Article Online
DOI: 10.1039/D6FO00521G
- 1021 55. F. C. Pereira, K. Wasmund, I. Cobankovic, N. Jehmlich, C. W. Herbold, K. S. Lee, B.
1022 Sziranyi, C. Vesely, T. Decker, R. Stocker, B. Warth, M. von Bergen, M. Wagner and D.
1023 Berry, Rational design of a microbial consortium of mucosal sugar utilizers reduces
1024 *Clostridiodes difficile* colonization, *Nature communications*, 2020, **11**, 5104.
- 1025 56. J. K. Volk, E. E. L. Nyström, S. van der Post, B. M. Abad, B. O. Schroeder, Å. Johansson, F.
1026 Svensson, S. Jäverfelt, M. E. V. Johansson, G. C. Hansson and G. M. H. Birchenough, The
1027 Nlrp6 inflammasome is not required for baseline colonic inner mucus layer formation or
1028 function, *The Journal of experimental medicine*, 2019, **216**, 2602-2618.
- 1029 57. Y. Du, D. X. Li, D. Y. Lu, R. Zhang, X. X. Zheng, B. J. Xu, Y. L. Zhao, S. Ji, M. Z. Guo, L.
1030 Wang and D. Q. Tang, *Morus alba* L. water extract changes gut microbiota and fecal
1031 metabolome in mice induced by high-fat and high-sucrose diet plus low-dose streptozotocin,
1032 *Phytotherapy research : PTR*, 2022, **36**, 1241-1257.
- 1033 58. Y. Lou, Y. Lv, X. Wang, Y. Luo, J. Lou, Y. Yu, W. Gu, J. Yu, Y. Fang, H. Zhao, K. Peng, J.
1034 Chen and Y. Ni, *Ruminococcus torques* ameliorates the inflammation bowel disease and gut
1035 barrier dysfunction by modulating gut microbiota and bile acid metabolism, *Journal of*
1036 *translational medicine*, 2025, **23**, 1162.
- 1037
- 1038



1040 **Table 1.** Maternal taurine supplementation on reproductive performance in pregnant
 1041 mice exposed to bisphenol A (BPA)


Items	Groups			SEM	<i>P</i> -value
	CON	BPA	BPA+Tau		
Initial BW (gestation day 0), g	20.27	20.27	20.27	0.224	1.000
BW (gestation day 18.5), g	33.96	32.01	33.55	0.640	0.092
Average placenta weight, g	0.10 ^a	0.08 ^b	0.09 ^{ab}	0.004	0.014
Average fetal weight, g	0.85 ^a	0.60 ^b	0.81 ^a	0.046	0.001
Total number of fetal	7.70 ^a	6.50 ^b	7.70 ^a	0.219	0.012
IUGR rate, %	20.79	28.05	19.56	2.726	0.098

1042 Notes: Values are presented as mean ± standard error of the mean (SEM).

1043 Within each row, values with different superscript lowercase letters (a, b) indicate a statistically significant
 1044 difference at the level of $P < 0.05$, while values sharing the same superscript letter indicate no significant
 1045 difference ($P \geq 0.05$). CON, control group; BPA, bisphenol A-exposed group; BPA+Tau, bisphenol A-exposed+
 1046 taurine; IUGR, intrauterine growth restriction; BW, body weight.


1047





1049

1050 **Fig. 1.** Schematic diagram of the experimental process.




1052

1053 **Fig. 2. Maternal taurine supplementation on oxidative stress and**1054 **inflammation-related biomarkers in serum and placental tissues of BPA-exposed**1055 **pregnant mice. (A) Serum antioxidant enzyme activity and malondialdehyde (MDA)**1056 **level; (B) Serum inflammatory cytokines; (C) Placental antioxidant enzyme activity**1057 **and malondialdehyde (MDA) level; (D) Placental inflammatory cytokines. CON,**1058 **control group; BPA, bisphenol A-exposed group; BPA+Tau, bisphenol A-exposed+**1059 **taurine. ns, no significance; * $P < 0.05$; ** $P < 0.01$; *** $P < 0.001$.**

1060








1062 Fig. 3. Maternal taurine supplementation on the expression levels of placental



1063 **function-associated genes, antioxidant and inflammatory cytokine in placental**
1064 **tissues of BPA-exposed pregnant mice.** (A) The mRNA abundance of placental
1065 function-related genes; (B) The mRNA abundance of antioxidant cytokine-related
1066 genes; (C) The mRNA abundance of inflammatory-related genes. CON, control group;
1067 BPA, bisphenol A-exposed group; BPA+Tau, bisphenol A-exposed+ taurine. ns, no
1068 significance; $0.05 \leq P < 0.10$, tendency towards significance; $*P < 0.05$; $**P < 0.01$;
1069 $***P < 0.001$.
1070






1073 **Fig. 4. Maternal taurine supplementation on the expression levels of antioxidant,**
1074 **inflammatory cytokine, and bile acid (BA) synthesis associated genes in liver**
1075 **tissues of BPA-exposed pregnant mice.** (A) The mRNA abundance of
1076 antioxidant-related genes; (B) The mRNA abundance of inflammatory
1077 cytokine-related genes; (C) The mRNA abundance of BA synthesis-related genes;
1078 CON, control group; BPA, bisphenol A-exposed group; BPA+Tau, bisphenol
1079 A-exposed+ taurine. ns, no significance; $0.05 \leq P < 0.10$, tendency towards
1080 significance; $*P < 0.05$; $**P < 0.01$; $***P < 0.001$.

1081






1083


1084 **Fig. 5. Maternal taurine supplementation on the expression levels of antioxidant**
 1085 **and inflammatory cytokine genes in fetal liver tissues of BPA- exposed pregnant**
 1086 **mice.** (A) The mRNA abundance of antioxidant-related genes; (B) The mRNA
 1087 abundance of inflammatory cytokine-related genes. CON, control group; BPA,
 1088 bisphenol A-exposed group; BPA+Tau, bisphenol A-exposed+ taurine. ns, no
 1089 significance; * $P < 0.05$; ** $P < 0.01$.





1090


1091 **Fig. 6. Maternal taurine supplementation on fecal microbiota community**1092 **diversity in BPA-exposed pregnant mice. (A) Shannon index; (B) Simpson index;**1093 **(C) Principal Coordinates Analysis (PCoA) based on weighted UniFrac distances at**1094 **the ASV level.**



1096
1097 **Fig. 7. Maternal taurine supplementation on fecal microbiota in BPA-exposed**
1098 **pregnant mice.** (A) Microbial composition at the genus level; (B-C) Differential
1099 analysis of microbial composition at the genus level; (D) Correlation analysis between
1100 serum antioxidant enzyme activity, inflammatory markers, and fecal microbiota. CON,
1101 control group; BPA, bisphenol A-exposed group; BPA+Tau, bisphenol A-exposed+
1102 taurine. ns, no significance; * $P < 0.05$; ** $P < 0.01$; *** $P < 0.001$.

1103






1104

1105 **Fig. 8. Maternal taurine supplementation on the bile acid (BA) metabolism in**1106 **serum of BPA-exposed pregnant mice. (A) PCA analysis; (B) Composition of BAs;**1107 **(C-Q) Composition of differential serum BAs. GCA, Glycocholic acid; TCA,**1108 **Taurocholic acid; TCDCA, Taurochenodeoxycholic acid; TUDCA,**1109 **Tauroursodeoxycholic acid; ACA, Apocholic acid; T- α -MCA,**1110 **Tauro-alpha-muricholic acid; T- β -MCA, Tauro-beta-muricholic acid; T- γ -MCA,**

1111 Tauro-gamma-muricholic acid; TLCA, Taurolithocholic acid; NCA, Norcholic acid;
1112 ILCA, Isolithocholic acid; DLCA, Dehydrolithocholic acid; LCA-3S, Lithocholic
1113 acid 3-sulfate; T- ω -MCA, Tauro-omega-muricholic acid; Total-TCBA, Total Tauro-
1114 conjugated bile acid; (R) Network analysis related to BA components; (S) Correlation
1115 analysis between differential BAs, oxidative stress markers, and inflammatory
1116 cytokines. MDA, Malondialdehyde; T-AOC, Total antioxidant capacity; SOD,
1117 Superoxide dismutase; IL-6, Interleukin-6; IL-8, Interleukin-8; IL-1 β ,
1118 Interleukin-1beta. One sample from the CON group and one sample from the
1119 BPA+Tau group were excluded due to hemolysis; final sample sizes were n = 9
1120 (CON), n = 10 (BPA), and n = 9 (BPA+Tau). $0.05 \leq P < 0.10$, tendency towards
1121 significance; * $P < 0.05$; ** $P < 0.01$; *** $P < 0.001$.

1122





1124

1125 **Fig. 9.** Summary chart for taurine mitigates BPA-induced maternal-fetal oxidative

1126 stress and improves fetal weight by regulating Nrf2-Keap1 pathway, inflammation,

1127 gut microbiota, and bile acid (BA) metabolism. This schematic illustrates how taurine

1128 mitigates BPA-induced maternal-fetal toxicity through multi-organ, synergistic

1129 regulation. BPA exposure disrupts the Nrf2-Keap1 pathway, triggering oxidative

1130 stress and inflammation that impair placental and hepatic function, disturb gut

1131 microbiota, and dysregulate BA metabolism, leading to fetal growth restriction.

1132 Taurine counteracts these effects by activating the Nrf2-Keap1 pathway to reduce

1133 oxidative stress and inflammation, restoring placental nutrient transport and hepatic

1134 metabolic homeostasis, while also remodeling gut microbiota and regulating the

1135 liver-gut microbiota-BA axis to normalize BA metabolism. These actions collectively

1136 reverse fetal growth restriction and maintain maternal-fetal metabolic and

1137 microecological homeostasis. BPA, Bisphenol A; Tau, Taurine; MDA,

1138 Malondialdehyde; SOD, Superoxide dismutase; Nrf2, Nuclear factor erythroid

1139 2-related factor 2; Keap1, Kelch-like ECH-associated protein 1; SOD1, Superoxide



1140 dismutase 1; SOD2, Superoxide dismutase 2; CAT, Catalase; TNF- α , Tumor necrosis
1141 factor- α ; IL-1 β , Interleukin-1 beta; IL-6, Interleukin-6; IL-8, Interleukin-8; SynB,
1142 Syncytin B; IGF2, Insulin-like growth factor 2; PPAR γ , Peroxisome
1143 proliferator-activated receptor γ ; CYP27A1, Cytochrome P450 family 27 subfamily A
1144 member 1; 7 α -HSDH, 7 α -Hydroxysteroid dehydrogenase; Bass family, bile acid
1145 sodium symporter family; ACA, Apocholic acid; LCA, Lithocholic acid.

View Article Online
DOI: 10.1039/C6FO00521G



Data availability statement

All data used for this study appear in the illustrated figures, and the raw data will promptly be made available upon request.

